Clinical purpose
Genetic information helps transform raw DNA data into actionable clinical decisions — especially in pharmacogenomics and reproductive carrier screening.
Genetic testing helps understand how the body responds to treatment and which inherited risks may play a role in prevention and care planning.
The new portfolio content turns each service area into a clearer story: what is measured, why it matters and how the report can be used.
Genetic information helps transform raw DNA data into actionable clinical decisions — especially in pharmacogenomics and reproductive carrier screening.
Pharmacogenetic testing analyses variants influencing drug metabolism, efficacy and adverse reaction risk across psychiatry, oncology, cardiology, pain management and other therapy areas.
Reports are structured for integration into clinical decision-making and can be interpreted by both clinicians and patients.
Testing variants in CYP2C9, VKORC1 and CYP2C19 to support warfarin dosing and clopidogrel efficacy.
A broad panel of genes influencing the metabolism of multiple medication groups.
Extended analysis of 27 LCT gene variants for a more precise assessment of lactose digestion.
Analysis of more than 7,400 genetic variants associated with serious congenital disorders and carrier status.
Analysis of CYP2C9 and VKORC1 variants for safer and more effective warfarin treatment.
CYP2C19 variant testing to verify metabolism and reduce the risk of ineffective or toxic therapy.
Some clients need a single targeted answer, others need a broader profile or a combination of biochemical and genetic context.
Contact us for individual, clinical or partner use of the diagnostics portfolio.
Contact us